Abstract
The high-resolution crystal structure of the N-terminal central region of bovine fibrinogen (a 35-kDa E5 fragment) reveals a remarkable dimeric design. The two halves of the molecule bond together at the center in an extensive molecular “handshake” by using both disulfide linkages and noncovalent contacts. On one face of the fragment, the Aα and Bβ chains from the two monomers form a funnel-shaped domain with an unusual hydrophobic cavity; here, on each of the two outer sides there appears to be a binding site for thrombin. On the opposite face, the N-terminal γ chains fold into a separate domain. Despite the chemical identity of the two halves of fibrinogen, an unusual pair of adjacent disulfide bonds locally constrain the two γ chains to adopt different conformations. The striking asymmetry of this domain may promote the known supercoiling of the protofibrils in fibrin. This information on the detailed topology of the E5 fragment permits the construction of a more detailed model than previously possible for the critical trimolecular junction of the protofibril in fibrin.
Fibrinogen, the key structural protein in blood clotting, has a unique and complex dimeric structure: the central so-called “E” region, critical for fibrin formation, contains a nexus of chains that bond the two identical halves of the molecule together in a small globular region (Fig. 1). Each monomer of this large (340-kDa) elongated (450-Å-long) molecule consists of three nonidentical chains, Aα, Bβ, and γ, and the N-terminal portions of the six chains are linked together by 11 disulfide bonds at the center. The C termini of each of the three chains also end in globular domains: those of the Bβ and γ chains are located at the ends, or D regions, and those of the Aα chains, the αC domains, appear to interact with each other close to the central E region. Except for an extended flexible portion of the αC domain, the regions between the globular domains in each half-molecule form α-helical coiled-coil structures, so that the E region consists of a globular region with two coiled-coil extensions (for review, see ref. 1).
When clotting occurs, thrombin cleaves two pairs of small negatively charged fibrinopeptides from the central E region, and soluble fibrinogen is converted into a relatively insoluble fibrin molecule, which self assembles to form the clot. In this process, the exposed N-terminal “knobs” of the α chains in one molecule of fibrin bind to receptor pockets in the terminal γC domains of adjacent molecules, leading to the formation of two-stranded half-staggered protofibrils (2, 3). The N-terminal knobs of the β chains are also exposed, and interactions between these knobs and receptor pockets in the βC domains may promote assembly of the protofibrils into fibers (4–6). Moreover, release of the fibrinopeptides by thrombin also appears to result in the dissociation of the αC domains from the central E region, and these domains can then promote assembly of protofibrils into fibers (7, 8). Lateral association of the protofibrils that produce thicker fibers does not appear to be as regular as the association of filaments within the two-stranded protofibril itself (9), and the specific lateral contacts made are only partially identified (6). The clot is strengthened by the covalent crosslinking of the end-to-end bonded γC domains (and, at a slower rate, of the αC domains). The clot is later dissolved by the action of plasmin, which produces various fragments of the molecule, including the D–D dimer and the E fragment.
The central E region has previously been visualized only at very low resolution in electron microscopic (10–14) or medium resolution by x-ray crystallographic (15, 16) studies of the proteolytically truncated or native molecules. At best, these data limit reliable chain traces to the relatively simple coiled-coil portions of the E region. To visualize the central region of the molecule in atomic detail, we have prepared a 35-kDa E5 fragment and determined its crystal structure to 1.4-Å resolution (see Methods). The results reveal that this chemical homodimer is conformationally asymmetric and consists of a strongly linked, highly convoluted interface between the two halves; they supplement as well our current picture of the molecular packing in the fibrin clot.
Methods
Protein Preparation and Characterization.
A 45-kDa fragment E was purified from a 2-h plasmic digest of bovine fibrinogen, as described previously (17, 18). This fragment was denoted as E3 because its N termini (AαLeu-23 or AαGln-27, BβLys-61, and γ Tyr-1) were equivalent to those reported for the human fibrinogen E3 fragment (19). Further digestion of bovine E3 fragment with chymotrypsin resulted in the appearance of two new discrete fragments with molecular masses of 40 and 35 kDa, denoted as E4 and E5, respectively (Fig. 1d). The complete amino acid sequence of bovine E5 was determined (Fig. 1c), and a comparison of this sequence with that of human fibrinogen E3 reveals that the generation of E5 is due to the removal of the N-terminal residues 23–28 from the Aα chain and several residues from the C termini of the Bβ and γ chains. The substantial decrease in the molecular mass as E3 is degraded to E5 can be attributed mainly to the stepwise removal of the carbohydrates linked to Asn-52 of each γ chain.
Crystallization and Structure Determination.
E5 was crystallized in two space groups: P21 (a = 49.4 Å, b = 66.2 Å, c = 50.7 Å, β = 106.6°) and P212121 (a = 53.4 Å, b = 58.8 Å, c = 96.8 Å). To ensure that the E5 fragment was not modified during crystallization, several (washed) crystals were analyzed: the N termini in the crystals were the same as in the starting material, and no free sulfhydryls were detected. By using x-ray diffraction data collected both on an R-AXIS IV detector system mounted on a Rigaku (Tokyo) x-ray generator and at synchrotron facilities (Table 1), the structure of the orthorhombic crystal form was solved (to 1.6-Å resolution) by a combination of single isomorphous replacement (using a trimethyllead-acetate derivative) and density modification. In this process, the α-helices of the coiled-coil regions were first identified in the electron density maps; their structures were subsequently used to obtain calculated phases that, when combined with the experimental data, led to completing the chain traces for the less regular central two domains of the fragment. Using this model, phases for the monoclinic crystal form were determined by molecular replacement, and the structure was refined to 1.4-Å resolution. The structure of E5 is very similar in the two space groups, except for small differences in the coiled-coil domain (see below). The N-terminal residues Aα29–34, Bβ61–63, and γ1 and the C-terminal residues Aα79–81 and Bβ115–116 were disordered in both halves of the molecule in each of the two crystal forms. Refinement statistics are found in Table 2. Additional protein preparation, purification, and crystallographic methods are published as supporting information on the PNAS web site (www.pnas.org).
Table 1.
Crystal | P21 (native) | P212121 (native) | P212121 (native) | P212121 (derivative)† | P212121 (derivative)† |
---|---|---|---|---|---|
X-ray source | CHESS | Rigaku | NSLS | Rigaku | NSLS |
Wavelength, Å | 0.91 | 1.54 | 1.087 | 1.54 | 1.087 |
Resolution, Å | 1.4 | 2.29 | 1.6 | 2.3 | 2.3 |
Unique reflections | 61,149 | 14,312 | 41,785 | 14,357 | 14,332 |
Total reflections | 359,638 | 115,257 | 1,321,351 | 123,405 | 320,778 |
Completeness, % | 99.2 | 99.3 | 99.4 | 99.0 | 99.9 |
Rsym* (%) | 5.8 (33.4) | 8.4 (26.0) | 5.9 (14.7) | 5.8 (16.3) | 9.2 (24.6) |
NSLS, National Synchrotron Light Source; CHESS, Cornell High Energy Synchrotion Source.
Rsym = ∑hkl ∑i | Ii − 〈I〉 |/∑hkl ∑iI; where 〈I〉 is the mean intensity of reflection hkl. The Rsym value for the highest-resolution shell (10% of unique data) is indicated in parentheses.
The derivative is Pb(CH3)3 OAc. See Methods for additional details.
Table 2.
Crystal | P21 | P212121 |
Resolution range, Å | 100.0–1.4 | 100.0–1.6 |
No. of protein atoms, waters | 2,200, 318 | 2,229, 312 |
Number of reflections | 58,431 | 40,453 |
Rfactor* (%), Rfree† (%) | 21.6, 23.6 | 19.4, 22.0 |
rms bond lengths, Å, angles (°) | 0.011, 1.46 | 0.010, 1.41 |
rms dihedrals (°), improper (°) | 19.4, 1.01 | 19.7, 1.03 |
Luzzati coordinate errors, Å | 0.20 | 0.18 |
Average B values, Å2 | 28.8 | 27.7 |
Rfactor = ∑hkl | | Fobs | − | Fcalc | |/∑hkl | Fobs |; where Fcalc and Fobs are respectively, the calculated and observed structure factor amplitudes for reflections hkl included in the refinement. σ cutoff = 0.
Rfree is the same as Rfactor but calculated over a randomly selected fraction (5%) of the reflection data not included in the refinement.
Results
Overall Domain Structure.
The dimeric rod-shaped E5 fragment may be divided into four closely interacting but distinct domains (Fig. 2), two of which are α-helical coiled-coil segments that extend along the long axis of the fragment. The N-terminal ends of the two coiled coils can be seen in the high-resolution E5 structure to be separated at the center by only 7 Å; the precise N-terminal residues of these coiled coils are AαSer-50, BβThr-85, and γThr-21. Here, the three chains within each monomer can be seen to be covalently linked by the previously predicted ring of three disulfide bonds, Aα48-γ23, γ19-Bβ87, and Bβ83-Aα52 (16, 20–22) (Fig. 3). The remaining N-terminal portions of all six chains are located for the most part surrounding, rather than between, the coiled coils (15) and form two additional domains in the central part of E5. In contrast to the coiled-coil domains, each of these two central domains includes chains from both monomers. The N-terminal portions of the Aα and Bβ chains in these monomers are located approximately on one face of the molecule (“up” in Figs. 2 and 3a), where together they form the rims and the walls of a funnel-shaped domain (Fig. 4), which is centered on the molecule's 2-fold axis. The N-terminal portions of both γ chains are located on the opposite face (“down” in Figs. 2 and 3a), where they form a distinct region that we call the “γN domain.” Four of the five disulfide bonds in these two central domains (Fig. 3a) previously predicted to connect the two halves of the molecule (16, 21, 23) are clearly seen in the E5 electron density maps. These are Aα39-Bβ′72 and Aα′39-Bβ72 in the funnel-shaped domain and γ8-γ′9 and γ′8-γ9 in the γN domain.** [The N-terminal residues Ser-29–Thr-34 of both Aα chains, however, are disordered, and consequently the bond between AαCys-31 and Aα′Cys-31 is not seen, although it is present in the crystals (see Methods)]. Numerous apolar and ionic contacts are made between the two coiled-coil domains and the funnel-shaped and γN-domains (as described in supporting information, www.pnas.org), consistent with the early prediction of strong interdomainal interactions within the E fragment from scanning calorimetry studies (17). Nevertheless, the disulfide bonds of the E5 fragment are either completely intradomainal (i.e., those that connect the two molecular halves in the funnel-shaped or γN domains) or provide a stabilizing cap for the N termini of the coiled coils; this arrangement of covalent linkages is in agreement with the picture that the structure consists of four independently folded domains.
The Coiled-Coil Domains of E5.
The α-helical coiled-coil domains of E5, consisting of residues Aα50–78, Bβ85–114, and γ21–48, have two noncanonical structural features. The sequences of coiled coils are characterized by their so-called “heptad repeat,” where every third then fourth residue is usually apolar and close-packed in the core (24) (for review, see ref. 25). In the E5 fragment, there is one three-residue deletion from the heptad repeat of each chain, located at homologous positions (Aα65, Bβ100, and γ36) midway along the coiled-coil domain (Fig. 1c). These deletions, or “stutters,” result in local non-close-packed cores as found in certain other coiled coils (26, 27). In addition, there is a proline residue in this stutter region of the Bβ chains at position 99 (Fig. 2). The location of this residue coincides with a bend in the Bβ-chain helix. The degree of bending varies (between ≈12 and 18°) in the two halves of the dimer and in the two crystal forms. The stutter and the proline residue are conserved among a number of vertebrate species, suggesting that these features, which promote flexibility, may be related to the functions of fibrinogen.
The Six Chains in the Central Region Produce a Highly Convoluted Dimeric Interface.
As seen in the crystal structure of fragment E5, the N-terminal portions of the Aα (residues 35–49) and Bβ (residues 64–84) chains from each subunit have distinct structural roles in the formation of the funnel-shaped domain. These segments of the Aα chains are located on the exterior of this domain perpendicular to the long axis of the molecule (Figs. 3a and 4). The most N-terminal residues of the Aα chains, Gly-35 and Trp-36, form part of the rim of the domain. The two chains diverge from one another (from residues 36 to 41) and subsequently converge (residues 43 to 49), so that they wrap around the Bβ chains.
In contrast to the Aα chains, the Bβ chains in the funnel-shaped domain extend along the long axis of the molecule and interact extensively with both coiled-coil domains (Figs. 2 and 4). The most N-terminal residues of the Bβ chains, 64–69, are in extended conformations and form the remainder of the central cavity's rim. Residues 70–84 of each Bβ chain form a relatively long loop containing a two-stranded antiparallel β-sheet. Residues 78 and 79, near the reverse turn of this loop, interact with the coiled-coil domain of the opposite monomer. One face of each loop is disulfide linked to the Aα chain portion of this domain, whereas the opposite face forms a major portion of the cavity's concave surface. This surface is unusual in being dominated by uncharged and hydrophobic amino acid side chains.
Each of the two γ chains in the γN-domain (residues 1–20), like the Bβ chains of the funnel-shaped domain, also contribute to the formation of a convoluted dimeric interface (Fig. 2). Following residues 4–7, which form short helices, and the disulfide-forming cysteines at positions 8 and 9, residues 10–16 of each γ chain also form a loop that interacts with the opposite subunit's coiled coil. Residues γ17–21 and γ′17–21 then fold back toward their respective coiled-coil domains, crisscrossing en route at residues γ19 and γ′19, which are part of a short antiparallel β-sheet and are located just below the funnel-shaped cavity described above.
The four loops formed by the Bβ and γ chains may be pictured as “fingers” that grasp each other and the coiled-coil domains in a firm “handshake” between the two half-molecules (Fig. 5). Such an intertwined structure yields a very large ≈2,500-Å2 contact area between the two halves of the E5 fragment (see Methods), which is greater than that found in many conventional protein dimers (28). It is apparent that the extensive interactions among the chains produce an exceptionally tight binding between the two molecular halves. In fact, the intertwined conformation of E5 is reminiscent of “3-D domain-swapped” dimers described by Eisenberg and colleagues (for review, see ref. 29), where two or more protein chains exchange identical elements to form a strongly bound oligomer. These many linkages would be expected to hold the two fibrinogen monomers together even without the intersubunit disulfide bonds.
Fibrinogen Is a Conformational Heterodimer.
One of the striking features of the E5 structure is that only part of the dimeric interface is symmetric. Residues 1–14 of the γ and γ′ chains are for the most part positioned to the side of the 2-fold axis of the molecule (Fig. 3a). Moreover, this portion of the γN domain is itself asymmetric, because the two chemically identical polypeptide segments adopt different conformations. This unusual feature is caused by the two reciprocal disulfide bonds between residues 8 and 9 of the γ and γ′ chains, which, as determined previously (30), locally orient these chains in an antiparallel manner. This design can be accounted for by recognizing that when two antiparallel β-strands are related by a 2-fold symmetric axis (as are residues γ18–20 and γ′18–20; see Fig. 3c), the side chains directly across from each other that are closest to the axis (such as γ19 and γ′19) must be the same. This type of register cannot occur in the N-terminal part of the γN domain, however, where residue 8 from one γ chain is covalently linked to residue 9 on the other (Fig. 3d). In this arrangement, the main-chain carbonyl oxygen of residue γ8 forms a hydrogen bond with the main-chain nitrogen of γ′9, but the main-chain carbonyl of γ′8 points away from the opposite subunit and forms a hydrogen bond with γ′11, resulting in markedly different conformations for the N-terminal 14 residues of the two chains (Fig. 3a). Moreover, this region contacts the stutter segment of the coiled-coil domain, which can bend differently in the two halves of the molecule. This heterodimeric structure of the E region reveals that fibrinogen, in a formal sense, is a polar molecule with respect to its long axis. This asymmetry may be significant for the formation of twisted protofibrils and fibers in fibrin (see below).
Discussion
Comparison to Previous Structures.
The crystallographic analyses of fibrinogen and its fragments have been pursued for a number of decades, but only in the past 5 years have atomic or near-atomic resolution results been achieved. The resolution of the E5 fragment crystal structure, at 1.4 Å, is the highest of any portion of fibrinogen or fibrin determined to date. Previously, structures of C-terminal fragments have also been determined to fairly high resolution (2.1–2.9 Å): these include the human γC domain (31) and fragments D and D–D (32–34). These results were critical for phasing the medium- to low-resolution data (4.0 and 5.5 Å) obtained, respectively, from crystals of the proteolytically truncated bovine (15) and intact chicken (16) fibrinogen molecules. Chain traces for the E region were also reported in the chicken fibrinogen molecule, but the conformations of the noncoiled-coil domains are significantly different from that of the bovine E5 fragment described here. We believe that these discrepancies, especially in the highly conserved γN chains, arise from the overinterpretation of the 5.5-Å resolution map of chicken fibrinogen.
Central Role for the E Region in Fibrin.
The structure of the E5 fragment of bovine fibrinogen provides information on the binding site for thrombin and the topology of the fibrin clot. The removal of Aα-chain fibrinopeptides A in fibrinogen by thrombin creates the N-terminal α knobs, consisting of gly-pro-arg (GPR) residues at positions 19–21 of the α chains, that fit into receptor pockets in the C-terminal γ domains during self assembly. Similarly, removal of Bβ-chain fibrinopeptides B creates the gly-his-arg (GHR) β knobs at positions 15–17 that appear to fit into pockets in the C-terminal β domains (see ref. 6). These residues, however, as well as additional parts of the native E region implicated in binding to thrombin [i.e., Bβ22–49 (35)], have been removed in the preparation of the E5 fragment (see Methods and Fig. 1). Nevertheless, because much of the central region has now been traced, we can locate the significant remaining portion of the thrombin-binding site; we can also estimate the general locations of the thrombin-exposed polymerization knobs more closely than previously (15) and thus improve the current model of the molecular packing in fibrin.
The Thrombin-Binding Sites in E5 Are Located on the Funnel-Shaped Domain.
Results from various studies on native and abnormal human fibrinogens indicate that the chain segments present in the E5 fragment implicated in the binding of thrombin include (in bovine numbering) Aα38–46 (35, 36) and Bβ75 (37). In each half of the E5 structure, these residues are located on the outer wall of the funnel-shaped domain and are positioned adjacent to one another, as one would expect for a composite binding site. Of the five surface-oriented residues in this Aα-chain segment (at positions 38, 40, 41, 42, and 45), Phe-38 may be of special note: this residue is closest to the rim of the funnel (in the presumed direction of the Aα knobs; see below), is the only apolar side chain (and is highly solvent accessible in E5), and is nearest Ala-75 of the Bβ chain. The binding site for thrombin does not appear to extend beyond Bβ75 (to the portion of the Bβ chain near the coiled-coil domains), because site-directed mutagenesis studies show that substitutions of Pro-77 and Leu-79 do not affect the kinetics of fibrinopeptide release by thrombin (38). The dimeric E5 structure also shows that the two composite thrombin-binding sites on the two molecular halves are well separated, by ≈35 Å, on opposite sides of the funnel-shaped domain (Fig. 4), such that two thrombin molecules can be accommodated simultaneously, in agreement with the measured stoichiometry (39).
The Locations and Functions of the Central Domains in the Protofibril of Fibrin.
The two-stranded protofibril of fibrin formed after reaction with thrombin can now be modeled by taking into account the domain structure of E5 (Fig. 6). In E5, residues Aα35 and Aα′35 (the most N-terminal residues traced) are located within 21 Å of each other, and weaker electron density seen in the bovine fibrinogen map (15) suggests that the disulfide bond between residues Aα31 and Aα′31 is positioned above the funnel-shaped cavity nearly coinciding with the 2-fold axis of the dimer (dotted lines in Fig. 3a). The two AαGPR knobs (only 10–12 residues away along the sequence at positions 19–21) are thus constrained to be located roughly on the same side of the molecule as the funnel-shaped domain. In a closed half-staggered protofibril of fibrin, we therefore expect that this domain of the E region from one filament would face the two closely situated γ-domain receptor pockets for these knobs on the adjacent filament (Fig. 6a). The E5 structure also indicates that the γN domain would be situated on the exterior side of the two-stranded protofibril and thus be positioned so that it might influence associations between protofibrils (see below).
Implications of γN-Domain Asymmetry.
The unusual structure of this γN domain illustrates the special role of a dimeric interface in protein folding and suggests how certain topological features of the fibrin fiber may be generated. Identical polypeptide chains generally fold into identical conformations. When two such chains are in a dimer, however, the interactions at their interface may have important conformational effects (40). Two of the most common dimerization motifs found in proteins—the antiparallel β-sheet and the parallel α-helical coiled-coil—generally form symmetrical structures with identically folded halves. It has recently been shown, however, that core alanines in the tropomyosin coiled coil disrupt the in-register symmetrical alignment of the chemically identical α-helices (41). In fragment E5, we now see how certain covalent disulfide bridges break the symmetry between two chemically identical antiparallel β-strand-like chains and, together with a number of noncovalent interactions, produce a compact asymmetric domain at the center of the molecule (see Results).
A functional role for the γN domain has not yet been established. Nevertheless, the asymmetry of this domain, which contacts the coiled-coil domains, may play a role in fibrin assembly. Molecules, protofibrils, and fibers of fibrin appear to display twisted conformations (9, 13, 42), and this asymmetry may be one feature that gives rise to the twisting. Moreover, the (probable) location of such a symmetry-breaking domain on the outside of the two-stranded protofibril (described above) may affect the uniformity of fibrin packing. It does not appear that the asymmetry would be propagated all the way to the positions of the α and β knobs, and the most direct implication of the location of the γN domain is that it should have little influence on the formation of individual protofibrils. If this were indeed the case, then successive fibrin molecules along the protofibril would not be arranged in a regular way with respect to this asymmetry (i.e., for some molecules γ would be situated to the “left” and γ′ to the “right;” for other molecules, the polarity could be reversed), and the exterior surfaces of any two extended protofibrils would generally differ (Fig. 6b). In this way, the asymmetry in the γN domain could contribute to disorder seen in the side-to-side packing between protofibrils (9, 43), depending on the actual contacts this domain may make.
Tying up Loose Ends.
With the crystallographic analysis of E5 in hand, the conformation of the entire “backbone” of the fibrinogen molecule has now been reliably described. However, the precise locations and structures of those residues that extend away from the molecule's long axis, including the αC domains and the N-terminal residues of the Aα and Bβ chains adjacent to the funnel-shaped domain, have yet to be determined; these segments have either been excised or are relatively disordered in the various crystallographic studies. Moreover, the function of the unusual largely apolar cavity in the funnel-shaped domain of E5 is unknown, but this region may turn out to interact with the adjacent N-terminal Aα- and/or Bβ-chain segments. The αC domains [poorly visualized in the native chicken fibrinogen structure (16)] appear to associate with each other to form a dimeric domain that is also located near the center of the E region in fibrinogen (7, 11, 12), but this binding appears to be most strongly mediated by the Bβ-chain segment that is released on thrombin cleavage (8). Knowledge of the functions of the apolar cavity thus awaits further studies and may require, for example, a high-resolution structure of a more complete E region fragment of fibrinogen. Even more revealing would be the structure of the trimeric DDE complex isolated from the fibrin clot. Knowledge of the detailed interactions in this complex will also test the basic protofibrillar model, including the relative orientations and possible functional roles of all four domains described here for E5.
Supplementary Material
Acknowledgments
We thank K. Ingham, S. Lord, and J. Weisel for critical reading of the manuscript, and M. Love, D. Himmel, and the staffs of the Brookhaven National Laboratory and the Cornell High Energy Synchrotron Source for assistance with data collection. This work was supported by grants from the National Institutes of Health (AR17346 to C.C. and HL-56051 to L.M.).
Footnotes
Data deposition: The atomic coordinates have been deposited in the Protein Data Bank, www.rcsb.org (PDB ID codes 1JY2 and 1JY3).
Note that the prime (′) in this manuscript is used exclusively to distinguish one half of the dimeric molecule from the other half; this same notation is also used elsewhere in the fibrinogen literature to refer to the alternatively spliced C terminus of the γ chain.
References
- 1.Doolittle R F, Everse S J, Spraggon G. FASEB J. 1996;10:1464–1470. doi: 10.1096/fasebj.10.13.8940292. [DOI] [PubMed] [Google Scholar]
- 2.Stryer L, Cohen C, Langridge R. Nature (London) 1963;197:793–794. doi: 10.1038/197793a0. [DOI] [PubMed] [Google Scholar]
- 3.Weisel J W, Phillips G N, Jr, Cohen C. In: Molecular Biology of Fibrinogen and Fibrin. Mosesson M W, Doolittle R F, editors. New York: NY Acad. Sci.; 1983. pp. 367–379. [Google Scholar]
- 4.Hantgan R, McDonagh J, Hermans J. In: Molecular Biology of Fibrinogen and Fibrin. Mosesson M W, Doolittle R F, editors. New York: NY Acad. Sci.; 1983. pp. 344–366. [Google Scholar]
- 5.Weisel J W, Veklich Y, Gorkun O. J Mol Biol. 1993;232:285–297. doi: 10.1006/jmbi.1993.1382. [DOI] [PubMed] [Google Scholar]
- 6.Yang Z, Mochalkin I, Doolittle R F. Proc Natl Acad Sci USA. 2000;97:14156–14161. doi: 10.1073/pnas.97.26.14156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Veklich Y I, Gorkun O V, Medved L V, Nieuwenhuizen W, Weisel J W. J Biol Chem. 1993;268:13577–13585. [PubMed] [Google Scholar]
- 8.Gorkun O V, Veklich Y I, Medved L V, Henschen A H, Weisel J W. Biochemistry. 1994;33:6986–6997. doi: 10.1021/bi00188a031. [DOI] [PubMed] [Google Scholar]
- 9.Weisel J W, Nagaswami C, Makowski L. Proc Natl Acad Sci USA. 1987;84:8991–8995. doi: 10.1073/pnas.84.24.8991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Hall C E, Slayter H S. J Biophys Biochem Cytol. 1959;5:11–17. doi: 10.1083/jcb.5.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Mosesson M W, Hainfeld J, Wall J, Haschemeyer R H. J Mol Biol. 1981;153:695–718. doi: 10.1016/0022-2836(81)90414-9. [DOI] [PubMed] [Google Scholar]
- 12.Erickson H P, Fowler W E. In: Molecular Biology of Fibrinogen and Fibrin. Mosesson M W, Doolittle R F, editors. New York: NY Acad. Sci.; 1983. pp. 146–163. [Google Scholar]
- 13.Williams R C. In: Molecular Biology of Fibrinogen and Fibrin. Mosesson M W, Doolittle R F, editors. New York: NY Acad. Sci.; 1983. pp. 180–193. [Google Scholar]
- 14.Weisel J W, Stauffacher C V, Bullitt E, Cohen C. Science. 1985;230:1388–1391. doi: 10.1126/science.4071058. [DOI] [PubMed] [Google Scholar]
- 15.Brown J H, Volkmann N, Jun G, Henschen-Edman A, Cohen C. Proc Natl Acad Sci USA. 2000;97:85–90. doi: 10.1073/pnas.97.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Yang Z, Mochalkin I, Veerapandian L, Riley M, Doolittle R F. Proc Natl Acad Sci USA. 2000;97:3907–3912. doi: 10.1073/pnas.080065697. . (First Published March 28, 2000; 10.1073/pnas.080065697) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Privalov P L, Medved L V. J Mol Biol. 1982;159:665–683. doi: 10.1016/0022-2836(82)90107-3. [DOI] [PubMed] [Google Scholar]
- 18.Medved L V, Platonova T N, Litvinovich S V, Lukinova N I. FEBS Lett. 1988;232:56–60. doi: 10.1016/0014-5793(88)80385-5. [DOI] [PubMed] [Google Scholar]
- 19.Olexa S A, Budzynski A Z, Doolittle R F, Cottrell B A, Greene T C. Biochemistry. 1981;20:6139–6145. doi: 10.1021/bi00524a035. [DOI] [PubMed] [Google Scholar]
- 20.Henschen A, McDonagh J. In: Blood Coagulation. Zwaal R F A, Hemker H C, editors. Amsterdam: Elsevier; 1986. pp. 171–241. [Google Scholar]
- 21.Blombäck B, Hessel B, Hogg D. Thromb Res. 1976;8:639–658. doi: 10.1016/0049-3848(76)90245-0. [DOI] [PubMed] [Google Scholar]
- 22.Doolittle R F, Goldbaum D M, Doolittle L R. J Mol Biol. 1978;120:311–325. doi: 10.1016/0022-2836(78)90070-0. [DOI] [PubMed] [Google Scholar]
- 23.Huang S, Cao Z, Davie E W. Biochem Biophys Res Commun. 1993;190:488–495. doi: 10.1006/bbrc.1993.1074. [DOI] [PubMed] [Google Scholar]
- 24.Crick F H C. Acta Crystallogr. 1953;6:689–697. [Google Scholar]
- 25.Cohen C, Parry D A D. Proteins Struct Funct Genet. 1990;7:1–15. doi: 10.1002/prot.340070102. [DOI] [PubMed] [Google Scholar]
- 26.Lupas A, Müller S, Goldie K, Engel A M, Engel A, Baumeister W. J Mol Biol. 1995;248:180–189. doi: 10.1006/jmbi.1995.0210. [DOI] [PubMed] [Google Scholar]
- 27.Brown J H, Cohen C, Parry D A D. Proteins Struct Funct Genet. 1996;26:134–145. doi: 10.1002/(SICI)1097-0134(199610)26:2<134::AID-PROT3>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
- 28.Janin J, Miller S, Chothia C. J Mol Biol. 1988;204:155–164. doi: 10.1016/0022-2836(88)90606-7. [DOI] [PubMed] [Google Scholar]
- 29.Schlunegger M P, Bennett M J, Eisenberg D. Adv Protein Chem. 1997;50:61–122. doi: 10.1016/s0065-3233(08)60319-8. [DOI] [PubMed] [Google Scholar]
- 30.Hoeprich P D, Doolittle R F. Biochemistry. 1983;22:2049–2055. doi: 10.1021/bi00278a003. [DOI] [PubMed] [Google Scholar]
- 31.Yee V C, Pratt K P, Côte H C, Trong I L, Chung D W, Davie E W, Stenkamp R E, Teller D C. Structure (London) 1997;5:125–138. doi: 10.1016/s0969-2126(97)00171-8. [DOI] [PubMed] [Google Scholar]
- 32.Spraggon G, Everse S J, Doolittle R F. Nature (London) 1997;389:455–462. doi: 10.1038/38947. [DOI] [PubMed] [Google Scholar]
- 33.Everse S J, Spraggon G, Veerapandian L, Riley M, Doolittle R F. Biochemistry. 1998;37:8637–8642. doi: 10.1021/bi9804129. [DOI] [PubMed] [Google Scholar]
- 34.Everse S J, Spraggon G, Veerapandian L, Doolittle R F. Biochemistry. 1999;38:2941–2946. doi: 10.1021/bi982626w. [DOI] [PubMed] [Google Scholar]
- 35.Binnie C G, Lord S T. Blood. 1993;81:3186–3192. [PubMed] [Google Scholar]
- 36.Stubbs M T, Oschkinat H, Mayr I, Huber R, Angliker H, Stone S R, Bode W. Eur J Biochem. 1992;206:187–195. doi: 10.1111/j.1432-1033.1992.tb16916.x. [DOI] [PubMed] [Google Scholar]
- 37.Koopman J, Haverkate F, Lord S T, Grimbergen J, Mannucci P M. J Clin Invest. 1992;90:238–244. doi: 10.1172/JCI115841. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Lord S T, Strickland E, Jaycock E. Biochemistry. 1996;35:2342–2348. doi: 10.1021/bi952353u. [DOI] [PubMed] [Google Scholar]
- 39.Meh D A, Siebenlist K R, Mossesson M W. J Biol Chem. 1996;271:23121–23125. doi: 10.1074/jbc.271.38.23121. [DOI] [PubMed] [Google Scholar]
- 40.Goodsell D S, Olson A J. Annu Rev Biophys Biomol Struct. 2000;29:105–153. doi: 10.1146/annurev.biophys.29.1.105. [DOI] [PubMed] [Google Scholar]
- 41.Brown J H, Kim K-H, Jun G, Greenfield N J, Dominguez R, Volkmann N, Hitchcock-DeGregori S E, Cohen C. Proc Natl Acad Sci USA. 2001;98:8496–8501. doi: 10.1073/pnas.131219198. . (First Published July 3, 2001; 10.1073/pnas.131219198). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Medved L V, Ugarova T, Veklich Y, Lukinova N, Weisel J. J Mol Biol. 1990;216:503–509. doi: 10.1016/0022-2836(90)90376-W. [DOI] [PubMed] [Google Scholar]
- 43.Voter W A, Lucaveche C, Blaurock A E, Erickson H P. Biopolymers. 1986;25:2359–2373. doi: 10.1002/bip.360251213. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.